Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer

Published:2024-08 Issue: Volume:207 Page:114196
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Pressiani Tiziana,Balsano Rita,Giordano Laura,Milella Michele,Bergamo Francesca,Bozzarelli Silvia,Noventa Silvia,Ferrrari Daris,Scartozzi Mario,Parra Hector Soto,Auriemma Alessandra,Soldà Caterina,Zaniboni Alberto,Zecchetto Camilla,Rizzato Mario Domenico,Rimassa Lorenza,Santoro Armando

Publisher

Elsevier BV

Reference26 articles.

1. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Vogel;Ann Oncol,2023

2. Biliary tract cancer;Valle;Lancet,2021

3. How I treat biliary tract cancer;Lamarca;ESMO Open,2022

4. Cholangiocarcinoma 2020: the next horizon in mechanisms and management;Banales;Nat Rev Gastroenterol Hepatol,2020

5. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer;Valle;N Engl J Med,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP